



GENENT.093A

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vanessa Hsei et al.) Group Art Unit 1644
Appl. No. : 09/234,182) I hereby certify that this correspondence and all
Filed : January 20, 1999) marked attachments are being deposited with the
For : ANTIBODY FRAGMENT) United States Postal Service as first-class mail in
POLYMER CONJUGATES) an envelope addressed to: United States Patent
AND HUMANIZED ANTI-IL-8) and Trademark Office, P.O. Box 2327,
MONOCLONAL ANTIBODIES) Arlington, VA 22202, on
Examiner : Dibrino, M.) February 22, 2002
(Date)
Ginger K. Dreger Reg. No. 33,055

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

The present response is filed concurrently with filing of a Request for Continued Examination of the above-identified patent application. Please enter the following amendments, and consider the following arguments.

In the Claims:

Please amend claim 1 to read as follows:

1. (Twice amended) A conjugate of a single antibody fragment covalently attached to a single polyethylene glycol (PEG) molecule, wherein the antibody fragment is a Fab' comprising (1) a first chain that is either a light chain or a heavy chain and (2) a first opposite chain that is either a heavy chain opposite the first light chain or a light chain opposite the first heavy chain, wherein the PEG molecule is covalently attached to a first cysteine residue in the first chain that would ordinarily form a disulfide bridge with a second cysteine residue in the first opposite chain, wherein the disulfide bridge is avoided by substitution of another amino acid

RECEIVED

MAR 11 2002

TECH CENTER 1600 2300